Becton Dickinson Pledges $19 Billion to Expand U.S. Medical Manufacturing

Becton Dickinson and Company (BDX.N) has struck a major deal with the U.S. government, becoming the first prominent medical device manufacturer to commit to expanding domestic production. The agreement, announced on Tuesday, involves a $19 billion investment over the coming years in exchange for protection against future tariffs. Under the terms, BD will allocate $3 billion to boost manufacturing operations across the United States, aiming to increase domestic production of critical medical supplies to about 80%. Shares of the company rose 2.4% in early trading following the news.

The deal is part of broader efforts by the Trump administration to strengthen U.S. healthcare manufacturing through tariff threats. BD’s commitments are tied to potential exemptions from tariffs on related products and raw materials under Section 232, contingent on meeting specific milestones. Jefferies analyst Matthew Taylor suggested that clarity on tariff policies could be a turning point for the medical technology sector, hinting at possible future announcements.

BD plans to significantly ramp up annual U.S. production, adding around 5 billion units of basic medical supplies. The company will also manufacture all needles for the U.S. market domestically using U.S.-made steel. While the financial impact of the agreement remains unquantified due to uncertainties around tariff rates and timelines, the deal follows President Donald Trump’s statement that BD will invest $3 billion to shift production to the U.S., with over $1 billion earmarked for Nebraska.

In January, BD announced a $110 million investment to expand syringe and needle production in Columbus, Nebraska, expected to create about 120 jobs. The new syringe products are slated to begin shipping to customers by mid-2026.